B cell targeted CAR-T therapy for autoimmune diseases

Qi Li; Ning Zhao; Ruitao Hou; Juliang Qin; Jiqin Zhang; Mingyao Liu; Bing Du

doi:10.1007/s11684-025-1191-x

B cell targeted CAR-T therapy for autoimmune diseases

Qi Li
, Ning Zhao
, Ruitao Hou
, Juliang Qin
, Jiqin Zhang
, Mingyao Liu^*
, Bing Du^*

^*Corresponding author for this work

School of Life Sciences

East China Normal University

Research output: Contribution to journal › Review article › peer-review

Abstract

Chimeric antigen receptor T (CAR-T) cells demonstrate remarkable effectiveness in targeting and eliminating pathogenic B-cell lineages, showing significant specificity and efficacy against B cell malignancies. In addition, CAR-T cell-mediated B cell depletion and resetting, which showed great potential in treating autoimmune diseases, thereby extending the clinical applicability of adoptive cell therapy. In this review, we examine the progression of CAR-T targeted B cell therapy for autoimmune diseases, encompassing the development of new therapeutic strategies and reports on related clinical outcomes. Furthermore, the article delves into the challenges and potential avenues for enhancement related to the safety aspects and inherent limitations of current technological solutions.

Original language	English
Journal	Frontiers of Medicine
DOIs	https://doi.org/10.1007/s11684-025-1191-x
State	Accepted/In press - 2025

Keywords

autoimmune diseases
chimeric antigen receptor-T therapy
clinical application
immune-mediated necrotizing myopathy
lymphodepletion
multiple sclerosis
myasthenia gravis
rheumatoid arthritis
systemic lupus erythematosus
systemic sclerosis

Access to Document

10.1007/s11684-025-1191-x

Cite this

@article{6df250dba0444d26a0a62c6d7e21378d,

title = "B cell targeted CAR-T therapy for autoimmune diseases",

abstract = "Chimeric antigen receptor T (CAR-T) cells demonstrate remarkable effectiveness in targeting and eliminating pathogenic B-cell lineages, showing significant specificity and efficacy against B cell malignancies. In addition, CAR-T cell-mediated B cell depletion and resetting, which showed great potential in treating autoimmune diseases, thereby extending the clinical applicability of adoptive cell therapy. In this review, we examine the progression of CAR-T targeted B cell therapy for autoimmune diseases, encompassing the development of new therapeutic strategies and reports on related clinical outcomes. Furthermore, the article delves into the challenges and potential avenues for enhancement related to the safety aspects and inherent limitations of current technological solutions.",

keywords = "autoimmune diseases, chimeric antigen receptor-T therapy, clinical application, immune-mediated necrotizing myopathy, lymphodepletion, multiple sclerosis, myasthenia gravis, rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis",

author = "Qi Li and Ning Zhao and Ruitao Hou and Juliang Qin and Jiqin Zhang and Mingyao Liu and Bing Du",

note = "Publisher Copyright: {\textcopyright} Higher Education Press 2025.",

year = "2025",

doi = "10.1007/s11684-025-1191-x",

language = "英语",

journal = "Frontiers of Medicine",

issn = "2095-0217",

publisher = "Springer Science + Business Media",

}

TY - JOUR

T1 - B cell targeted CAR-T therapy for autoimmune diseases

AU - Li, Qi

AU - Zhao, Ning

AU - Hou, Ruitao

AU - Qin, Juliang

AU - Zhang, Jiqin

AU - Liu, Mingyao

AU - Du, Bing

N1 - Publisher Copyright: © Higher Education Press 2025.

PY - 2025

Y1 - 2025

N2 - Chimeric antigen receptor T (CAR-T) cells demonstrate remarkable effectiveness in targeting and eliminating pathogenic B-cell lineages, showing significant specificity and efficacy against B cell malignancies. In addition, CAR-T cell-mediated B cell depletion and resetting, which showed great potential in treating autoimmune diseases, thereby extending the clinical applicability of adoptive cell therapy. In this review, we examine the progression of CAR-T targeted B cell therapy for autoimmune diseases, encompassing the development of new therapeutic strategies and reports on related clinical outcomes. Furthermore, the article delves into the challenges and potential avenues for enhancement related to the safety aspects and inherent limitations of current technological solutions.

AB - Chimeric antigen receptor T (CAR-T) cells demonstrate remarkable effectiveness in targeting and eliminating pathogenic B-cell lineages, showing significant specificity and efficacy against B cell malignancies. In addition, CAR-T cell-mediated B cell depletion and resetting, which showed great potential in treating autoimmune diseases, thereby extending the clinical applicability of adoptive cell therapy. In this review, we examine the progression of CAR-T targeted B cell therapy for autoimmune diseases, encompassing the development of new therapeutic strategies and reports on related clinical outcomes. Furthermore, the article delves into the challenges and potential avenues for enhancement related to the safety aspects and inherent limitations of current technological solutions.

KW - autoimmune diseases

KW - chimeric antigen receptor-T therapy

KW - clinical application

KW - immune-mediated necrotizing myopathy

KW - lymphodepletion

KW - multiple sclerosis

KW - myasthenia gravis

KW - rheumatoid arthritis

KW - systemic lupus erythematosus

KW - systemic sclerosis

UR - https://www.scopus.com/pages/publications/105026258806

U2 - 10.1007/s11684-025-1191-x

DO - 10.1007/s11684-025-1191-x

M3 - 文献综述

AN - SCOPUS:105026258806

SN - 2095-0217

JO - Frontiers of Medicine

JF - Frontiers of Medicine

ER -

B cell targeted CAR-T therapy for autoimmune diseases

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this